Form 8-K - Current report:
SEC Accession No. 0000950170-25-076482
Filing Date
2025-05-22
Accepted
2025-05-22 17:29:01
Documents
15
Period of Report
2025-05-22
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apvo-20250522.htm   iXBRL 8-K 56713
2 EX-5.1 apvo-ex5_1.htm EX-5.1 38540
3 EX-99.1 apvo-ex99_1.htm EX-99.1 19096
4 GRAPHIC img57496738_0.jpg GRAPHIC 18656
5 GRAPHIC img57496738_1.jpg GRAPHIC 21696
6 GRAPHIC img57496738_2.jpg GRAPHIC 18656
  Complete submission text file 0000950170-25-076482.txt   315347

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apvo-20250522.xsd EX-101.SCH 24892
17 EXTRACTED XBRL INSTANCE DOCUMENT apvo-20250522_htm.xml XML 4697
Mailing Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121
Business Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121 206-838-0500
Aptevo Therapeutics Inc. (Filer) CIK: 0001671584 (see all company filings)

EIN.: 811567056 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37746 | Film No.: 25978368
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)